Bioventix Plc Posting of Annual Report and Notice of AGM

 
TIDMBVXP 
 
Bioventix plc 
                        ("Bioventix" or the "Company") 
 
                  Posting of Annual Report and Notice of AGM 
 
Bioventix plc (BVXP), a UK company specialising in the development and 
commercial supply of high-affinity monoclonal antibodies for applications in 
clinical diagnostics, confirms that its Annual Report and Accounts for the year 
ended 30 June 2021 and the Notice of Annual General Meeting ("AGM") has been 
posted to shareholders. 
 
These documents are available on the Company's website at www.bioventix.com. 
 
The AGM will be held at Farnham Castle, Farnham, Surrey, GU9 0AG at 2.00 p.m. 
on 9 December 2021. 
 
The Board continues to monitor the situation surrounding COVID-19 and the 
advice from the Government on public gatherings. If the Government's guidance 
changes at any point prior to the AGM, such that shareholders are unable to 
attend in person, the Company will update shareholders through an announcement 
to the London Stock Exchange and on the Company's website. In light of this 
uncertainty, the Board strongly encourages shareholders to submit a proxy vote 
in advance of the AGM and to appoint the Chairman of the AGM as their proxy, 
rather than a named person who, if circumstances change, may not the able to 
attend the AGM. 
 
For further information please contact: 
 
Bioventix plc                                     Tel: [phone] 
Peter Harrison           Chief Executive Officer 
Bruce Hiscock            Chief Financial Officer 
 
finnCap Ltd                                       Tel: [phone] 
Geoff Nash/Simon Hicks   Corporate Finance 
Alice Lane               ECM 
 
About Bioventix plc: 
 
Bioventix (www.bioventix.com) specialises in the development and commercial 
supply of high-affinity monoclonal antibodies with a primary focus on their 
application in clinical diagnostics, such as in automated immunoassays used in 
blood testing. The antibodies created at Bioventix are generated in sheep and 
are of particular benefit where the target is present at low concentration and 
where conventional monoclonal or polyclonal antibodies have failed to produce a 
suitable reagent. Bioventix currently offers a portfolio of antibodies to 
customers for both commercial use and R&D purposes, for the diagnosis or 
monitoring of a broad range of conditions, including heart disease, cancer, 
fertility, thyroid function and drug abuse. Bioventix currently supplies 
antibody products and services to the majority of multinational clinical 
diagnostics companies. Bioventix is based in Farnham, UK and its shares are 
traded on AIM under the symbol BVXP. 
 
 
 
END 
 
 

(END) Dow Jones Newswires

November 11, 2021 09:32 ET (14:32 GMT)